Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average volume of 165 put options.
Insider Buying and Selling
In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now owns 31,302 shares in the company, valued at $1,258,340.40. The trade was a 41.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,492 shares of company stock worth $2,334,969 over the last quarter. 5.52% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of XENE. Blue Trust Inc. raised its holdings in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 641 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at $63,000. Quarry LP bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at $78,000. Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at $101,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after purchasing an additional 487 shares in the last quarter. Institutional investors own 95.45% of the company's stock.
Xenon Pharmaceuticals Trading Up 0.7 %
XENE stock traded up $0.29 during midday trading on Friday, reaching $39.67. The company had a trading volume of 104,501 shares, compared to its average volume of 416,505. The company has a market capitalization of $3.02 billion, a P/E ratio of -14.05 and a beta of 1.20. The company has a 50 day moving average of $39.45 and a two-hundred day moving average of $40.40. Xenon Pharmaceuticals has a 1 year low of $35.53 and a 1 year high of $50.99.
Analyst Ratings Changes
Several brokerages have commented on XENE. Needham & Company LLC restated a "buy" rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $57.38.
View Our Latest Research Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
